Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06630104

Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)

Led by Mayo Clinic · Updated on 2026-01-08

82

Participants Needed

7

Research Sites

159 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This clinical trial evaluates the impact of preexisting and therapy-emergent germline and somatic variants on cytopenia in patients with multiple myeloma or CD19 positive lymphoproliferative disorder (LPD) following chimeric antigen receptor T-cell (CAR-T) therapy. The most common adverse event after CAR-T therapy is lower than normal blood cells (cytopenia) and up to one third of patients experience cytopenia that last longer than 30 days post-infusion. Germline and somatic variants are changes in genes found using cancer genomic tests. Cancer genetic/genomic testing is a series of tests that find specific changes in cancer cells or in blood deoxyribonucleic acid. Identifying gene mutations may help identify the risk of cytopenia in patients with multiple myeloma or CD19 positive LPD following CAR-T therapy.

CONDITIONS

Official Title

Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 218 years
  • Confirmed diagnosis of multiple myeloma based on International Myeloma Working Group criteria or CD19 positive lymphoproliferative disorder based on 2016 WHO classification
  • Provide written informed consent
  • Willing to provide mandatory bone marrow aspirate specimens during clinical procedures for research
  • Willing to provide mandatory hair follicle specimens for research
  • Willing to provide saliva and buccal samples for research
  • Willing to return to enrolling institution for follow-up during active monitoring phase
Not Eligible

You will not qualify if you...

  • Not eligible for CAR-T therapy
  • Diagnosed with myeloid neoplasm before CAR-T therapy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

Mayo Clinic in Arizona

Scottsdale, Arizona, United States, 85259

Actively Recruiting

2

Mayo Clinic in Florida

Jacksonville, Florida, United States, 32224-9980

Actively Recruiting

3

Mayo Clinic Health System in Albert Lea

Albert Lea, Minnesota, United States, 56007

Actively Recruiting

4

Mayo Clinic Health System-Mankato

Mankato, Minnesota, United States, 56001

Actively Recruiting

5

Mayo Clinic in Rochester

Rochester, Minnesota, United States, 55905

Actively Recruiting

6

Mayo Clinic Health System-Eau Claire Clinic

Eau Claire, Wisconsin, United States, 54701

Actively Recruiting

7

Mayo Clinic Health System-Franciscan Healthcare

La Crosse, Wisconsin, United States, 54601

Actively Recruiting

Loading map...

Research Team

C

Clinical Trials Referral Office

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here